Home Compliance Novo Nordisk Settles Allegations of Improperly Sourced Injection Needles, for $6.3 Million ComplianceFCANews Novo Nordisk Settles Allegations of Improperly Sourced Injection Needles, for $6.3 Million September 9, 2022 15 Share FacebookLinkedinTwitter ravipat | Shutterstock You must be a Paid or Free Trial Member to Access this Content. Paid members, please login to view your news subscription(s). RELATED ARTICLESMORE FROM AUTHOR Compliance Wages War Over: Ohio Court Rules SCA Violations Weren’t FCA Violations Compliance Relator’s Claims Against Federal Grantees Survive Motion to Dismiss Compliance DOJ’s First Intervention in Cybersecurity FCA Qui Tam Case Signals Continued Cyber Enforcement